Pfizer and BioNTech SE conducted the final efficacy analysis in their ongoing Phase III study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, meeting all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection and also in participants with and without prior SARS-CoV-2 infection, in each case measured from 28 days after the first dose, 7 days after the second dose. The first primary obj...